8-K: Astrana Health Reports Strong Q3 Revenue, Updates 2025 Outlook

Astrana Health, Inc. announced solid third-quarter 2025 financial results, including 100% year-over-year revenue growth, while updating full-year guidance due to contract delays.

Summary

• Total revenue for the third quarter ended September 30, 2025, was $956.0 million, representing a 100% increase year-over-year and reaching the higher end of guidance.
• Adjusted EBITDA for Q3 2025 was $68.5 million, up 52% from the prior year, also at the higher end of guidance.
• Net income attributable to Astrana Health, Inc. for Q3 2025 was $0.4 million, a significant decrease from $16.1 million in Q3 2024.
• Diluted earnings per share for Q3 2025 was $0.01, down from $0.33 in Q3 2024.
• The acquisition of Prospect Health was completed on July 1, 2025, with its standalone third-quarter performance exceeding expectations.
• Full-year 2025 guidance was updated, with total revenue now projected between $3,100 million and $3,180 million, and Adjusted EBITDA between $200 million and $210 million.
• The update to full-year guidance accounts for delays in certain full-risk contract transitions, which are now expected to be completed in the first quarter of 2026.
• Care Partners revenue grew 97% to $897.7 million in Q3 2025.
• 77% of Q3 2025 capitation revenue was derived from fully capitated arrangements, an increase from 60% a year ago.
• Net cash provided by operating activities for the nine months ended September 30, 2025, was $117.483 million, up from $63.146 million in the same period of 2024.
• Total assets increased to $2,237.186 million as of September 30, 2025, from $1,354.894 million as of December 31, 2024.
• Long-term debt, net of current portion, increased to $1,002.026 million as of September 30, 2025, from $425.299 million as of December 31, 2024.

Sentiment

Score: 6

Explanation: While revenue and adjusted EBITDA were strong and at the high end of guidance, and the acquisition performed well, the significant drop in net income and diluted EPS, coupled with the delay in full-risk contract transitions and increased debt, presents a mixed financial picture. The underlying business performance is described as strong, but the delays temper the immediate outlook.

Positives

• Total revenue for Q3 2025 increased 100% year-over-year to $956.0 million, reaching the higher end of guidance.
• Adjusted EBITDA for Q3 2025 increased 52% year-over-year to $68.5 million, also at the higher end of guidance.
• The Prospect Health acquisition was successfully completed, and its standalone performance exceeded expectations.
• Strong momentum in combined operations with Prospect Health, expanding scale, capabilities, and physician reach across key markets.
• Underlying clinical and cost trend performance across both the legacy Astrana and Prospect businesses remain strong.
• A strategic partnership was announced with Intermountain Health to expand access to coordinated, high-quality care across southern Nevada.
• A new partnership was announced with a provider group in Southern California within the Care Enablement business, serving over 40,000 members in value-based care arrangements.
• Increasing alignment through total cost of care responsibility, with 77% of Q3 2025 capitation revenue coming from fully capitated arrangements, up from 60% a year ago.
• Net cash provided by operating activities significantly increased to $117.483 million for the nine months ended September 30, 2025, from $63.146 million in the prior year period.

Negatives

• Net income attributable to Astrana Health, Inc. significantly decreased to $0.4 million in Q3 2025 from $16.1 million in Q3 2024.
• Diluted earnings per share decreased to $0.01 in Q3 2025 from $0.33 in Q3 2024.
• Adjusted EBITDA margin decreased to 7% in Q3 2025 from 9% in Q3 2024.
• Income from operations decreased to $19.210 million in Q3 2025 from $28.425 million in Q3 2024.
• Full-year 2025 guidance was updated to account for full-risk contract delays, indicating a revised outlook.
• Long-term debt, net of current portion, increased significantly to $1,002.026 million as of September 30, 2025, from $425.299 million as of December 31, 2024.
• Working capital decreased to $253.7 million as of September 30, 2025, from $272.9 million as of December 31, 2024.

Risks

• Full-risk contract transitions are delayed and are now expected to be completed in the first quarter of 2026, impacting the full-year outlook.
• A legal matter with a provider associated with CFC Health Plan, Inc. ("CFC HP") resulted in $13.0 million in expenses for the three months ended September 30, 2025.

Future Outlook

Astrana Health updated its full-year 2025 guidance for total revenue to a range of $3,100 million to $3,180 million and Adjusted EBITDA to a range of $200 million to $210 million. This update accounts for delays in full-risk contract transitions, which are now expected to be completed in the first quarter of 2026. The company anticipates continued strong underlying clinical and cost trend performance across its businesses and expects to achieve $12-15 million in OpEx synergies from the Prospect transaction within 12-18 months.

Management Comments

• "Astrana delivered solid third quarter results and demonstrated strong momentum in our first quarter of combined operations with Prospect Health." Brandon Sim, President and Chief Executive Officer.
• "Prospects performance exceeded our expectations, and integration is progressing well, expanding our scale, capabilities, and physician reach across key markets." Brandon Sim, President and Chief Executive Officer.
• "While our full-year outlook reflects the updated timing of certain full-risk contract transitions, which we expect to complete in the first quarter of 2026, underlying clinical and cost trend performance across both the legacy Astrana and Prospect businesses remain strong." Brandon Sim, President and Chief Executive Officer.
• "We continue to execute with discipline and focus on building a more coordinated, high-quality, and accessible care delivery platform for the long term." Brandon Sim, President and Chief Executive Officer.

Industry Context

The filing highlights Astrana Health's continued expansion in the value-based care sector, a growing trend in the U.S. healthcare system aimed at improving patient outcomes and managing costs. The acquisition of Prospect Health and the partnership with Intermountain Health demonstrate a strategy of consolidating provider networks and integrating technology to enhance care delivery, aligning with broader industry shifts towards more coordinated and efficient healthcare models. The focus on increasing full-risk arrangements reflects a deeper commitment to value-based care, where providers assume greater financial responsibility for patient outcomes.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct comparison.
• Astrana Health's strategic focus on increasing full-risk contracts (77% of Q3 2025 capitation revenue) aligns with the broader industry trend towards value-based care models, which are increasingly favored by payers and regulators for their potential to improve outcomes and control costs compared to traditional fee-for-service models.
• The successful integration and better-than-expected performance of the Prospect Health acquisition suggest effective execution in a competitive M&A environment within the healthcare services sector.

Legal Proceedings

• A legal matter with a provider associated with CFC Health Plan, Inc. ("CFC HP") resulted in $13.0 million in "Other, net" expenses for the three months ended September 30, 2025.

Stakeholder Impact

• Shareholders: Mixed impact due to strong revenue growth and successful acquisition offset by a significant drop in net income and diluted EPS, and updated guidance due to delays.
• Providers: Expanded network and capabilities through Prospect Health acquisition and new partnerships, enhancing reach and value-based care arrangements.
• Patients: Expanded access to coordinated, high-quality care through strategic partnerships and increased value-based care arrangements.
• Creditors: Increased long-term debt to over $1 billion, indicating higher leverage.
• Employees: Integration efforts from the Prospect acquisition are progressing, with expected OpEx synergies potentially impacting staffing.

Next Steps

• Complete full-risk contract transitions in the first quarter of 2026.
• Onboard a new provider group in Southern California to the Astrana platform in the first half of 2026.
• Achieve $12-15 million in OpEx synergies from the Prospect transaction within 12-18 months.
• Host a conference call and webcast on November 6, 2025, at 2:30 p.m. PT/5:30 p.m. ET to discuss Q3 2025 results.

Key Dates

Recommendation

While Astrana Health demonstrated robust revenue and Adjusted EBITDA growth, driven by a successful acquisition, the substantial decline in net income and diluted EPS, coupled with the delay in full-risk contract transitions, introduces uncertainty. The increased leverage from debt financing for the acquisition also warrants caution. Investors should hold to observe the successful integration of Prospect Health, the resolution of contract delays, and the realization of anticipated synergies before making further investment decisions. The underlying business trends are positive, but the immediate financial performance and outlook are mixed.

Keywords

Healthcare, Value-based care, Provider network, Medical groups, Health plan, Acquisition, Financial results, Q3 2025, Astrana Health, ASTH, Adjusted EBITDA, Revenue, SEC filing, 8-K